Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.62

€0.62

-0.810%
-0.005
-0.810%
-
 
16.07.24 / Frankfurt WKN: A402TW / Name: Tevogen Bio Hldgs Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Tevogen Bio Hldgs Inc. Stock

Tevogen Bio Hldgs Inc. shows a slight decrease today, losing -€0.005 (-0.810%) compared to yesterday.

Pros and Cons of Tevogen Bio Hldgs Inc. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant: https://mms.businesswire.com/media/20240320704564/en/1911946/5/Tevogen_Logo_Businesswire.jpg
Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant


Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of